By continuing to use the site you agree to our Privacy & Cookies policy

Breast cancer drug exemestane may increase fracture risk

Women taking the anti-breast cancer drug exemestane (Aromasin) should have regular bone monitoring to assess fracture risk because the treatment speeds up loss of bone density, a study suggests.

Get unlimited access

As a subscriber you will benefit from:

  • Full online and mobile access to news and opinion stories
  • Customised email alerts straight to your inbox (over 30 alerts available)
  • 4,500 practice articles in our archive 
  • Over £500 worth of CPD learning units